Communiqués XOMA Corporation Nasdaq

Actions

XOMAP

US98419J3059

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 20/06/2024			Varia. 5j.	Varia. 1 janv.
25,43 ^USD	+0,20%		-0,35%	+0,08%

09/05	XOMA Corporation publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
30/04	XOMA Corporation (NasdaqGM:XOMA) a complété l'acquisition de trois actifs de première catégorie de Daré Bioscience, Inc. (NasdaqCM:DARE) pour 22 millions de dollars.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

XOMA Declares Quarterly Preferred Stock Dividends	20/06	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	13/06	AQ
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher	12/06	AQ
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	14/05	AQ
Xoma: Q1 Earnings Snapshot	09/05	AQ
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	09/05	AQ
XOMA : 2024 Letter to Shareholders	09/05	PU
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	30/04	AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04	AQ
XOMA : Acquisition/Asset Disposal - Form 8-K	03/04	PU
XOMA Corporation Announces Closing of Tender Offer	03/04	AQ
XOMA Declares Quarterly Preferred Stock Dividends	21/03	AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03	AQ
Xoma: Q4 Earnings Snapshot	08/03	AQ
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08/03	AQ
XOMA to Present at Upcoming Investor Conferences in March	28/02	AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02	AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16/02	PR
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	16/02	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	19/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués XOMA Corporation Nasdaq

Actions

XOMAP

US98419J3059

Communiqués

Filtres